CROI 2024 Abstract eBook

Abstract eBook

Poster Abstracts

requirements. Also, a sensitivity analysis was conducted to compare the interaction between vaccination and contact tracing rates. Results: Our model demonstrated cell-level contact tracing was relatively ineffective by itself (3.2% PIA), but its effectiveness increased when combined with other interventions (i.e., vaccination or jail release). Each of the other intervention strategies produced a PIA > 10% independently, with the 13% jail release scenario producing a PIA of nearly 20%. The all-level contact tracing only scenario was effective at both 50% and 100% of contacts traced, but feasibility is limited without a reduction in the jail population. Conclusion: Implementing combined interventions could substantially reduce the morbidity and mortality from COVID-19 and future airborne pathogens in a jail setting while providing secondary protection to the community.

record from January 2, 2021 and June 14, 2022 to identify the vaccination status. Outcome was any SARS-CoV-2 infection. Then we compared the odds of vaccination between test-positive cases and test-negative controls using logistic regression models in different period of circulating VOC, adjusting for include age, sex, race/ethnicity, and number of comorbidities (Charlson Comorbidity Score [CCI]). VE was derived as (1-adjusted odds ratio)×100%. Results: Among a total of 6,239 PWH, 2,180 were test-positive cases and 4,059 were test negative controls. Among them, 48.3% aged 50 years and above, 68.7% were male, 71.2% were black. The coverage rate of fully vaccination rate was similar between cases (33.0%) and controls (32.0%), while a higher coverage of booster dose (8.3%) was observed among cases than controls (7.0%). When stratified by different VOC, VE was 61.47% and 79.31% for partial and fully vaccination status in the Alpha dominant period. In the Delta dominant period, VE was 13.88%, 37.46%, and 69.17% for partial, fully, and booster vaccination status. In the Omicron dominant period, the VE was only 22.20% for individuals who received booster dose. When look at the VE in different vaccine brands, BNT162b2 indicated a higher VE during Alpha period, mRNA-1273 revealed a high VE (54.26%) during Delta period. In contrast, Ad26.COV2.S showed the higher VE during Omicron period. Conclusion: The VE against SARS-CoV-2 infection among PWH substantially decreased during Omicron dominant period compared with the other periods. Fully vaccination, especially boosted vaccination, offered sustained protection prior to the emergency of the Omicron VOC. In terms of vaccine brands, our findings suggested that both BNT162b2 and Ad26.COV2.S had lasting protection effect prior to the Omicron period while the protection effect of mRNA-1273 gradually diminished along with periods.

Poster Abstracts

1211 A Network-Based Modeling Analysis of Interventions for SARS-CoV-2 Prevention Among Jailed Adults Isaac Schneider 1 , Karina Wallrafen-Sam 1 , Shanika Kennedy 1 , Matthew Akiyama 2 , Anne C. Spaulding 1 , Samuel M. Jenness 1 1 Emory University, Atlanta, GA, USA, 2 Albert Einstein College of Medicine, Bronx, NY, USA Background: Managing COVID-19 in jails/prisons is challenging due to high density of contacts. The state of Georgia has limited COVID vaccine uptake plus high incarceration. Using a network-based SARS-CoV-2 transmission model parameterized with data from Atlanta GA's Fulton County Jail (FCJ, population 3000, rated capacity 2600), this study investigates the impact of three SARS CoV-2 prevention strategies: vaccination, contact tracing and quarantining, and release of residents to decrease population to the jail's capacity. Methods: Contact networks were simulated at 2 different overlapping network layers: cell and housing block. Cell-level contacts represented shared confined sleeping space, whereas block-level contacts represented shared common space. Contact tracing and quarantining were simulated at the cell-level, or both the cell- and block- levels. A reference scenario and 9 intervention scenarios using different combinations of the 3 prevention strategies – vaccination, contact tracing/quarantining, and resident release – were simulated to estimate median and interquartile range (IQR) of the outcome measures. Each scenario was simulated 300 times with each simulation measuring the prolonged effects of the interventions amid a potential COVID outbreak in the jail over a 185-day period. The cumulative incidence, number of infections averted (NIA), and percentage of infections averted (PIA) were calculated for all scenarios. For the 7 scenarios involving contact tracing and quarantining, total quarantines and the number of quarantines/day were calculated to determine the quarantine

1212 Safety Outcomes in Trial of COVID-19 mRNA Vaccine Among People With HIV in Sub- Saharan Africa Simone L Hendricks 1 , Bongile Mabilane 1 , Asa Tapley 1 , Jia Jin Kee 1 , Veronique Bailey 1 , Ethel Kamuti 2 , Harriet Nuwagaba-Biribonwoha 3 , Zvavahera Chirenje 4 , Joseph M. Makhema 5 , Taraz Samandari 6 , Laura Polakowski 7 , Manuel Villaran 1 , Nyaradzo Mgodi 4 , Azwidihwi Takalani 1 , for the CoVPN 3008 Ubuntu Study Team 1 Fred Hutchinson Cancer Center, Seattle, WA, USA, 2 Centre for Infectious Disease Research in Zambia, Lusaka, Zambia, 3 ICAP at Columbia University, New York, NY, USA, 4 University of Zimbabwe, Harare, Zimbabwe, 5 Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana, 6 US Centers for Disease Control and Prevention Kisumu, Kisumu, Kenya, 7 National Institute of Allergy and Infectious Diseases, Baltimore, MD, USA Background: CoVPN 3008 (Ubuntu), the largest multicenter phase 3/4 trial of mRNA vaccines in sub-Saharan Africa (SSA), provided a unique opportunity to prospectively study safety outcomes among people with HIV (PWH). Methods: The study enrolled adults age ≥18 years living with HIV or another comorbidity associated with severe Covid-19, who were not previously vaccinated. Participants were assigned vaccinations based on their baseline point-of-care SARS-CoV-2 serostatus: those with a positive result received one dose at baseline, those with a negative result received a dose at baseline and month 1. There were no exclusions for pregnancy, HIV viral load, CD4 count, or antiretroviral therapy (ART) use. Solicited local and systemic adverse events (AEs) (for 7 days after each injection) and unsolicited AEs (for 28 days after

CROI 2024 396